UBX - Unity Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Unity Biotechnology, Inc.

3280 Bayshore Boulevard
Suite 100
Brisbane, CA 94005
United States

Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Mr. Keith R. Leonard Jr.Exec. Chairman & CEO896.02kN/A1962
Dr. Nathaniel E. DavidCo-Founder, Pres & Exec. Director2.25MN/A1968
Dr. Jamie DananbergChief Medical Officer559.19kN/A1958
Dr. Jan M. van DeursenFounderN/AN/AN/A
Dr. Judith CampisiFounderN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Corporate Governance

Unity Biotechnology, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.